Crinetics Pharmaceuticals (CRNX) FY2025 10-K Risk Factors: 6 New, 19 Dropped

What the changes say

Crinetics transitioned to a commercial-stage company following FDA approval of PALSONIFY for acromegaly in September 2025.
Financial success now heavily relies on successfully launching and commercializing PALSONIFY and advancing pipeline assets like atumelnant.
The company faces ongoing reliance on third-party manufacturers without redundant supply arrangements for key raw materials.

What changed since the prior 10-K

New

NewRisks related to our limited operating history, financial position and capital requirements
Risks related to the discovery and development and regulatory approval of our product candidates and the commercialization of PALSONIFY
The business now heavily depends on the commercial success of PALSONIFY, which received FDA approval in September 2025 to treat acromegaly.
NewRisks related to our limited operating history, financial position and capital requirements
If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize PALSONIFY or our other product candidates
Future revenue relies entirely on successfully commercializing PALSONIFY and developing other pipeline candidates like atumelnant.
NewRisks related to commercialization of PALSONIFY and our product candidates
U.S., the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future
Third-party payors may refuse coverage or offer low reimbursement if cheaper generic alternatives or substitutable therapies are available.
NewRisks related to commercialization of PALSONIFY and our product candidates
We obtained regulatory approval from the FDA for PALSONIFY but have limited demonstration of conducting commercial activities
Having just received FDA approval for PALSONIFY in September 2025, we have limited experience conducting long-term sales and marketing activities.
NewRisks related to our reliance on third parties
penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products
We lack redundant supply or second sources for all required raw materials, active pharmaceutical ingredients, and drug intermediaries.
NewRisks related to our common stock
for the resolution of any complaint asserting a cause of action arising under the Securities Act, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees
Our bylaws designate the Delaware Court of Chancery as the exclusive forum for internal corporate disputes, while federal district courts are exclusive for Securities Act claims.

Dropped

DroppedRisks related to our limited operating history, financial position and capital requirements
our ability to participate in any future equity offering by Radionetics
DroppedRisks related to the discovery and development and regulatory approval of our product candidates
We have two product candidates in clinical development, and all of our other research programs are still in the preclinical or discovery stage. If we are unable to successfully develop any product candidates or experience significant delays in doing so, our business will be materially harmed
DroppedRisks related to the discovery and development and regulatory approval of our product candidates
maintaining and growing an organization of scientists and businesspeople who can develop our products and technology
Radionetics equity offering participation
DroppedRisks related to the discovery and development and regulatory approval of our product candidates
delays in our clinical trials resulting from external factors including global conflicts or health epidemics
Having two clinical-stage product candidates
DroppedRisks related to the discovery and development and regulatory approval of our product candidates
studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of our clinical development program
Building an organization of scientists and businesspeople
DroppedRisks related to the discovery and development and regulatory approval of our product candidates
the FDA or other comparable foreign regulatory authorities may experience disruptions to the review or approval process
DroppedRisks related to the discovery and development and regulatory approval of our product candidates
which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate
DroppedRisks related to the discovery and development and regulatory approval of our product candidates
We have conducted, and continue to conduct, clinical trials for our current product candidates outside of the United States, and we may do so for our other product candidates. However, conducting trials outside of the United States exposes us to additional risks, which could materially harm our business
Clinical trial delays from global conflicts or epidemics
DroppedRisks related to the discovery and development and regulatory approval of our product candidates
interruptions or delays in our trials resulting from geopolitical events, such as war or terrorism
DroppedRisks related to commercialization of our product candidates
injunctions or the imposition of civil or criminal penalties
DroppedRisks related to commercialization of our product candidates
the public perception regarding any products we may develop
Regulatory objections to clinical trial designs
DroppedRisks related to our business operations and industry
We conduct certain research and development operations through our Australian wholly-owned subsidiary. If we lose our ability to operate in Australia, or if our subsidiary is unable to receive the research and development tax credit allowed by Australian regulations, our business and results of operations could suffer
Regulatory disruptions to review processes
DroppedRisks related to our business operations and industry
facts and circumstances, we could be subject to criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA
Retaining sole commercialization rights
DroppedRisks related to our business operations and industry
Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. It is unclear how any such challenges and the healthcare reform measures of the current administration, or any future presidential administration, will impact the ACA or our business
Risks of conducting clinical trials outside the U.S.
DroppedRisks related to our business operations and industry
a decline in our stock price
Geopolitical interruptions including Brexit
DroppedRisks related to our intellectual property
countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates
DroppedRisks related to our intellectual property
require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology
DroppedRisks related to our common stock
intellectual property, product liability or other litigation by or against us
Injunctions or imposition of civil or criminal penalties
DroppedRisks related to our common stock
the timing and success or failure of preclinical studies or clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners

Reworded

91% rewrittenRisks related to our business operations and industry
Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our products and product candidates and may affect the prices we may set
Added specific mention of heightened U.S. governmental scrutiny of pharmaceutical pricing practices amidst rising prescription drug costs.
Was: Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set
89% rewrittenRisks related to our limited operating history, financial position and capital requirements
Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming and which may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates
Expanded regulatory compliance scope to include international authorities beyond the FDA.
81% rewrittenRisks related to our business operations and industry
Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could have a material adverse effect on our business, financial condition or results of operations
Retained standard data privacy and security risk language with minor stylistic updates.
67% rewrittenRisks related to our limited operating history, financial position and capital requirements
For the foregoing reasons, we cannot be certain that our ongoing and planned clinical trials and preclinical studies will be successful, and the failure of any our product candidates could have a material adverse effect on our business, financial condition and results of operations
Retained clinical trial uncertainty and failure risk language with minor stylistic updates.
62% rewrittenRisks related to our limited operating history, financial position and capital requirements
We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could lead us to delay, limit, reduce, abandon or terminate our product development programs, commercialization efforts or other operations
Updated to reflect ongoing commercialization efforts for PALSONIFY alongside clinical development of paltusotine and atumelnant.
61% rewrittenRisks related to our common stock
Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide
Added bullet point formatting to operational fluctuation factors and updated references from product candidates to products.
57% rewrittenRisks related to our business operations and industry
If product liability or state consumer protection act lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products
Expanded product liability risks to explicitly cover commercialized products alongside clinical trial candidates.
57% rewrittenRisks related to our limited operating history, financial position and capital requirements
We have a limited operating history, have incurred significant operating losses since our inception and expect to continue to incur losses. We may never become profitable or, if we achieve profitability, we may not be able to sustain it
Updated operating history to reflect commercial launch activities and FDA regulatory approval for PALSONIFY.
Was: We have a limited operating history, have incurred significant operating losses since our inception and expect to continue to incur losses. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it
54% rewrittenRisks related to commercialization of PALSONIFY and our product candidates
The commercial success of PALSONIFY and our other product candidates, if approved, will depend upon the degree of market acceptance by physicians, patients, health care payors and others in the medical community
Was: The commercial success of our product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, health care payors and others in the medical community
50% rewrittenRisks related to our intellectual property
Changes in U.S. patent law, or laws in other countries or jurisdictions, could diminish the value of patents in general, thereby impairing our ability to protect our products and product candidates
Was: Changes in U.S. patent law, or laws in other countries or jurisdictions, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
50% rewrittenRisks related to our intellectual property
Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts
49% rewrittenRisks related to commercialization of PALSONIFY and our product candidates
We have sought and may continue to seek to enter into collaborations, licenses and other similar arrangements of our product and may not be successful in doing so, and even if we are, we may not realize the benefits of such relationships
39% rewrittenRisks related to our common stock
Our ability to use net operating loss carryforwards and other tax attributes may be limited
33% rewrittenRisks related to our common stock
Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management
30% rewrittenRisks related to our limited operating history, financial position and capital requirements
Changes in U.S. and international trade policies, particularly with respect to China, Europe and India may adversely impact our business and operating results
30% rewrittenRisks related to our business operations and industry
The increasing use of social media and artificial intelligence-based platforms presents new risks and challenges
28% rewrittenRisks related to our reliance on third parties
We rely on third parties to conduct many of our preclinical studies and clinical trials. Any failure by a third party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates
27% rewrittenRisks related to our intellectual property
Our success depends on our ability to protect our intellectual property and our proprietary technologies, and if we are unable to protect our intellectual property and technologies, our business will suffer
26% rewrittenRisks related to our business operations and industry
We may encounter difficulties in managing our growth and expanding our operations successfully
26% rewrittenRisks related to our intellectual property
We may not be able to protect our intellectual property rights throughout the world
23% rewrittenRisks related to our common stock
Unfavorable global economic conditions could adversely affect our business, financial condition and stock price
22% rewrittenRisks related to our common stock
The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses

All 67 risk factors

Headings as the filing states them, in filing order.

Risks related to our limited operating history, financial position and capital requirements

01We have a limited operating history, have incurred significant operating losses since our inception and expect to continue to incur losses. We may never become profitable or, if we achieve profitability, we may not be able to sustain it57% rewritten
02We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could lead us to delay, limit, reduce, abandon or terminate our product development programs, commercialization efforts or other operations62% rewritten
03Risks related to the discovery and development and regulatory approval of our product candidates and the commercialization of PALSONIFYNew
04If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize PALSONIFY or our other product candidatesNew
05We cannot assure you that we will be able to successfully discover and develop additional product candidates
06For the foregoing reasons, we cannot be certain that our ongoing and planned clinical trials and preclinical studies will be successful, and the failure of any our product candidates could have a material adverse effect on our business, financial condition and results of operations67% rewritten
07Use of our products and product candidates could be associated with side effects or adverse events during their development or commercialization, which could severely harm our business, reputation, prospects, operating results and financial condition
08Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming and which may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates89% rewritten
09Changes in U.S. and international trade policies, particularly with respect to China, Europe and India may adversely impact our business and operating results30% rewritten
10Initial, interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and is subject to audit and verification procedures that could result in material changes in the final data

Risks related to commercialization of PALSONIFY and our product candidates

11The occurrence of any event or penalty described above may inhibit our ability to commercialize PALSONIFY and our other product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity
12Disruptions at the FDA and other government agencies could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business
13The commercial success of PALSONIFY and our other product candidates, if approved, will depend upon the degree of market acceptance by physicians, patients, health care payors and others in the medical community54% rewritten
14U.S., the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the futureNew
15The numbers of patients suffering from the rare endocrine diseases and endocrine-related tumors that we target is small and have not been established with precision. If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer
16We have sought and may continue to seek to enter into collaborations, licenses and other similar arrangements of our product and may not be successful in doing so, and even if we are, we may not realize the benefits of such relationships49% rewritten
17We obtained regulatory approval from the FDA for PALSONIFY but have limited demonstration of conducting commercial activitiesNew
18Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties

Risks related to our reliance on third parties

19We rely on third parties to conduct many of our preclinical studies and clinical trials. Any failure by a third party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates28% rewritten
20penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our productsNew
21Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us
22Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed

Risks related to our business operations and industry

23We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer
24We may encounter difficulties in managing our growth and expanding our operations successfully26% rewritten
25We are subject to various foreign, federal and state healthcare laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition
26Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could have a material adverse effect on our business, financial condition or results of operations81% rewritten
27Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our products and product candidates and may affect the prices we may set91% rewritten
28If product liability or state consumer protection act lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products57% rewritten
29We and any of our potential future collaborators will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business
30Our employees and independent contractors, including principal investigators, CROs, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
31We may not realize any benefits from our relationship with Radionetics
32The increasing use of social media and artificial intelligence-based platforms presents new risks and challenges30% rewritten

Risks related to our intellectual property

33Our success depends on our ability to protect our intellectual property and our proprietary technologies, and if we are unable to protect our intellectual property and technologies, our business will suffer27% rewritten
34If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be material and adversely affected
35We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court
36Intellectual property rights do not necessarily address all potential threats to our competitive advantage
37Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts50% rewritten
38Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline
39Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party
40Changes in U.S. patent law, or laws in other countries or jurisdictions, could diminish the value of patents in general, thereby impairing our ability to protect our products and product candidates50% rewritten
41We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
42Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
43If we do not obtain patent term extension for our product candidates, our business may be materially harmed
44We may not be able to protect our intellectual property rights throughout the world26% rewritten
45Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
46If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
47If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
48We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers

Risks related to our common stock

49An active, liquid and orderly market for our common stock may not be maintained
50The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses22% rewritten
51Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval
52We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock
53Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall
54Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management33% rewritten
55for the resolution of any complaint asserting a cause of action arising under the Securities Act, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employeesNew
56Our ability to use net operating loss carryforwards and other tax attributes may be limited39% rewritten
57Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
58We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management
59Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide61% rewritten
60We and any of our third-party manufacturers and suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly
61Our information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs
62Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
63Unfavorable global economic conditions could adversely affect our business, financial condition and stock price23% rewritten
64If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline
65The increasing focus and evolving expectations with respect to on environmental sustainability and social initiatives could increase our costs, harm our reputation and adversely impact our financial results
66Changes in tax laws may impact our financial condition and results of operations
67We could be subject to securities class action litigation

Other Crinetics Pharmaceuticals 10-Ks

FY2024 10-K risk factors
80 risks
Crinetics is a clinical-stage biopharmaceutical company developing paltusotine and atumelnant for rare endocrine diseases and tumors.
Filed Feb 27, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.